Medicenna Therapeutics (MDNA) Insider Trading & Ownership C$0.99 0.00 (0.00%) As of 03/25/2025 03:59 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock Medicenna Therapeutics (TSE:MDNA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage22.57%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)C$29,645.00Number OfInsiders Selling(Last 12 Months)0 Get MDNA Insider Trade Alerts Want to know when executives and insiders are buying or selling Medicenna Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address MDNA Insider Buying and Selling by Quarter Remove Ads Medicenna Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/13/2025Albert George BeraldoDirectorBuy500C$1.29C$645.001/9/2025David HymanSenior OfficerBuy20,000C$1.45C$29,000.00 (Data available from 1/1/2013 forward) MDNA Insider Trading Activity - Frequently Asked Questions Who is on Medicenna Therapeutics's Insider Roster? The list of insiders at Medicenna Therapeutics includes Albert George Beraldo, Chandra Panchal, and David Hyman. Learn more on insiders at MDNA. What percentage of Medicenna Therapeutics stock is owned by insiders? 22.57% of Medicenna Therapeutics stock is owned by insiders. Learn more on MDNA's insider holdings. Which Medicenna Therapeutics insiders have been buying company stock? The following insiders have purchased MDNA shares in the last 24 months: Albert George Beraldo (C$645.00), and David Hyman (C$29,000.00). How much insider buying is happening at Medicenna Therapeutics? Insiders have purchased a total of 20,500 MDNA shares in the last 24 months for a total of C$29,645.00 bought. Medicenna Therapeutics Key ExecutivesDr. Fahar Merchant Ph.D. (Age 67)Founder, Chairman, President & CEO Compensation: $454.37kMs. Rosemina Merchant B.Sc. (Age 67)M.E.Sc, Founder & Chief Development Officer Compensation: $364.46kMr. David Hyman CA (Age 51)CBV, Chief Financial Officer Dr. Samuel R. Denmeade M.D.Scientific Advisor More Insider Trading Tools from MarketBeat Related Companies Fennec Pharmaceuticals Insider Trades Andean Precious Metals Insider Trades Cardiol Therapeutics Insider Trades Gear Energy Insider Trades Canadian Gold Insider Trades Relevant Gold Insider Trades Ascendant Resources Insider Trades Niobay Metals Insider Trades Galore Resources Insider Trades Pacific Bay Minerals Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles NVIDIA Insiders Sell: This Is What It Means for the Market Top 3 Insider Stock Buys in March—Are They Still Good in April?Grocery Outlet Insider and Institutional Buyers Signal BottomSentinelOne Insider Selling? Why Investors Should Stay Bullish 3 Companies Buying Back Stock—Why It Matters This page (TSE:MDNA) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicenna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
